Inhibition of histone acetyltransferase by glycosaminoglycans

Journal of Cellular Biochemistry

Volumn 105, Issue 1, 2008, Pages 108-120

  Buczek Thomas, Jo Ann ^a   Hsia, Edward ^a   Rich, Celeste B ^a   Foster, Judith A ^a   Nugent, Matthew A ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Boston University   (United States)

Author keywords

Glycosaminoglycans; Heparan sulfate; Heparin; Histone acetyltransferase; p300; pCAF; Proteoglycans

Indexed keywords

DNA; GLYCOSAMINOGLYCAN; HEPARIN; HEPARIN DERIVATIVE; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE; HISTONE H3; HISTONE H4; PROTEIN P300; PROTEOGLYCAN; PROTEOHEPARAN SULFATE; RECOMBINANT PROTEIN; SULFUR 35;

ACETYLATION; ANIMAL CELL; ARTICLE; CHO CELL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORNEA CELL; ENZYME ASSAY; ENZYME INHIBITION; IN VITRO STUDY; ISOTOPE LABELING; LUNG FIBROBLAST; NEOPLASM; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT;

ACETYLATION; ANIMALS; CELL NUCLEUS; CELLS, CULTURED; CRICETINAE; EYE; FIBROBLASTS; GLYCOSAMINOGLYCANS; HISTONE ACETYLTRANSFERASES; HISTONES; HUMANS; LUNG; SUBSTRATE SPECIFICITY;

CRICETULUS GRISEUS;

EID: 51849166854     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21803     Document Type: Article

References (72)

1. Ait-Si-Ali S, Ramirez S, Barre FX, Dkhissi F, Magnaghi-Jaulin L, Girault JA, Robin P, Knibiehler M, Pritchard LL, Ducommun B, Trouche D, Harel-Bellan A. 1998. Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A. Nature 396:184-186.
2. Ambrosio AL, Iglesias MM, Wolfenstein-Todel C. 1997. The heparin-binding lectin from ovine placenta: Purification and identification as histone H4. Glycoconj J 14:831-836.
3. Balasubramanyam K, Swaminathan V, Ranganathan A, Kundu TK. 2003. Small molecule modulators of histone acetyltransferase p300. J Biol Chem 278:19134-19140.
4. Barnes PJ, Adcock IM, Ito K. 2005. Histone acetylation and deacetylation: Importance in inflammatory lung diseases. Eur Respir J 25:552-563.
5. Bassols A, Massagué J. 1988. Transforming growth factor β regulates the expression and structure of extracellular matrix chondroitin/dermatan sulfate proteoglycans. J Biol Chem 263:3039-3045.
6. Berger SL. 2001. Molecular biology. The histone modification circus. Science 292:64-65.
7. Brown CT, Nugent MA, Lau FW, Trinkaus-Randall V. 1999. Characterization of proteoglycans synthesized by cultured corneal fibroblasts in response to transforming growth factor beta and fetal calf serum. J Biol Chem 274:7111-7119.
8. Brown CE, Lechner T, Howe L, Workman JL. 2000. The many HATs of transcription coactivators. Trends Biochem Sci 25:15-19.
9. Brown CT, Lin P, Walsh MT, Gantz D, Nugent MA, Trinkaus-Randall V. 2002. Extraction and purification of decorin from corneal stroma retain structure and biological activity. Protein Expr Purif 25:389-399.
10. Buczek-Thomas JA, Nugent MA. 1999. Elastase-mediated release of heparan sulfate proteoglycans from pulmonary fibroblast cultures. A mechanism for basic fibroblast growth factor (bFGF) release and attenuation of bfgf binding following elastase-induced injury. J Biol Chem 274:25167-25172.
11. Buczek-Thomas JA, Chu CL, Rich CB, Stone PJ, Foster JA, Nugent MA. 2002. Heparan sulfate depletion within pulmonary fibroblasts: Implications for elastogenesis and repair. J Cell Physiol 192:294-303.
12. Carreras I, Rich CB, Panchenko MP, Foster JA. 2002. Basic fibroblast growth factor decreases elastin gene transcription in aortic smooth muscle cells. J Cell Biochem 85:592-600.
13. Carrozza MJ, Utley RT, Workman JL, Cote J. 2003. The diverse functions of histone acetyltransferase complexes. Trends Genet 19:321-329.
14. Castellot JJ, Cochran DL, Karnovsky MJ. 1985a. Effect of heparin on vascular smooth muscle cells. I. Cell metabolism. J Cell Physiol 124:21-28.
15. Castellot JJ, Wong K, Herman B, Hoover RL, Albertini DF, Wright TC, Caleb BL, Karnovsky MJ. 1985b. Binding and internalization of heparin by vascular smooth muscle cells. J Cell Physiol 124:13-20.
16. Connolly DT, Knight MB, Harakas NK, Wittwer AJ, Feder J. 1986. Determination of the number of endothelial cells in culture using an acid phosphatase assay. Anal Biochem 152:136-140.
17. Conrad HE. 1998. Heparin-binding proteins. San Diego: Academic Press.
18. Coradini D, Pellizzaro C, Abolafio G, Bosco M, Scarlata I, Cantoni S, Stucchi L, Zorzet S, Turrin C, Sava G, Perbellini A, Daidone MG. 2004. Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study. Invest New Drugs 22:207-217.
19. Cullis PM, Wolfenden R, Cousens LS, Alberts BM. 1982. Inhibition of histone acetylation by N-[2-(S-coenzyme A)acetyl] spermidine amide, a multisubstrate analog. J Biol Chem 257:12165-12169.
20. Du Clos TW, Volzer MA, Hahn FF, Xiao R, Mold C, Searles RP. 1999. Chromatin clearance in C57Bl/10 mice: Interaction with heparan sulphate proteoglycans and receptors on Kupffer cells. Clin Exp Immunol 117:403-411.
21. Eliseeva ED, Valkov V, Jung M, Jung MO. 2007. Characterization of novel inhibitors of histone acetyltransferases. Mol Cancer Ther 6:2391-2398.
22. Esko J. 1992. Animal cell mutants defective in heparan sulfate polymerization. In: Lane DA, Bjork J, Lindall U, editors. Heparin and related polysaccharides. New York: Plenum Press. pp 97-106.
23. Esko JD, Selleck SB. 2002. Order out of chaos: Assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 71:435-471.
24. Farndale RW, Buttle DJ, Barrett AJ. 1986. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 883:173-177.
25. Fedarko NS, Conrad HE. 1986. A unique heparan sulfate in the nuclei of hepatocytes: Structural changes with the growth state of the cells. J Cell Biol 102:587-599.
26. Fedarko NS, Ishihara M, Conrad E. 1989. Control of cell division in hepatoma cells by exogenous heparan sulfate proteoglycan. J Cell Physiol 139:287-294.
27. Forsten KE, Courant NA, Nugent MA. 1997. Endothelial proteoglycans inhibit bFGF binding and mitogenesis. J Cell Physiol 172:209-220.
28. Foster JA, Rich CB, Miller MF. 1990. Pulmonary fibroblasts: An in vitro model of emphysema. Regulation of elastin gene expression. J Biol Chem 265:15544-15549.
29. Fry CJ, Peterson CL. 2002. Transcription. Unlocking the gates to gene expression. Science 295:1847-1848.
30. Gallagher JT. 2001. Heparan sulfate: Growth control with a restricted sequence menu. J Clin Invest 108:357-361.
31. Gregory PD, Wagner K, Horz W. 2001. Histone acetylation and chromatin remodeling. Exp Cell Res 265:195-202.
32. Hascall VC, Majors AK, De La Motte CA, Evanko SP, Wang A, Drazba JA, Strong SA, Wight TN. 2004. Intracellular hyaluronan: A new frontier for inflammation? Biochim Biophys Acta 1673:3-12.
33. Hildebrand CE, Tobey RA, Gurley LR, Walters RA. 1978. Action of heparin on mammalian nuclei. II. Cell-cycle-specific changes in chromatin organization correlate temporally with histone H1 phosphorylation. Biochim Biophys Acta 517:486-499.
34. Hiscock DR, Yanagishita M, Hascall VC. 1994. Nuclear localization of glycosaminoglycans in rat ovarian granulosa cells. J Biol Chem 269: 4539-4546.
35. Horn PJ, Peterson CL. 2002. Molecular biology. Chromatin higher order folding-wrapping up transcription. Science 297:1824-1827.
36. Hsia E, Richardson TP, Nugent MA. 2003. Nuclear localization of basic fibroblast growth factor is mediated by heparan sulfate proteoglycans through protein kinase C signaling. J Cell Biochem 88:1214-1225.
37. Ishihara M, Conrad HE. 1989. Correlations between heparan sulfate metabolism and hepatoma growth. J Cell Physiol 138:467-476.
38. Ishihara M, Fedarko NS, Conrad HE. 1986. Transport of heparan sulfate into the nuclei of hepatocytes. J Biol Chem 261:13575-13580.
39. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ. 2005. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 352:1967-1976.
40. Johnson CA. 2000. Chromatin modification and disease. J Med Genet 37:905-915.
41. Kornberg RD, Lorch Y. 1999. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 98:285-294.
42. Kovalszky I, Dudas J, Olah-Nagy J, Pogany G, Tovary J, Timar J, Kopper L, Jeney A, Iozzo RV. 1998. Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor. Mol Cell Biochem 183:11-23.
43. Lau OD, Courtney AD, Vassilev A, Marzilli LA, Cotter RJ, Nakatani Y, Cole PA. 2000a. p300/CBP-associated factor histone acetyltransferase processing of a peptide substrate. Kinetic analysis of the catalytic mechanism. J Biol Chem 275:21953-21959.
44. Lau OD, Kundu TK, Soccio RE, Ait-Si-Ali S, Khalil EM, Vassilev A, Wolffe AP, Nakatani Y, Roeder RG, Cole PA. 2000b. HATs off: Selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell 5:589-595.
45. Legube G, Trouche D. 2003. Regulating histone acetyltransferases and deacetylases. EMBO Rep 4:944-947.
46. Liang Y, Haring M, Roughley PJ, Margolis RK, Margolis RU. 1997. Glypican and biglycan in the nuclei of neurons and glioma cells: Presence of functional nuclear localization signals and dynamic changes in glypican during the cell cycle. J Cell Biol 139:851-864.
47. Mai A, Rotili D, Tarantino D, Ornaghi P, Tosi F, Vicidomini C, Sbardella G, Nebbioso A, Miceli M, Altucci L, Filetici P. 2006. Small-molecule inhibitors of histone acetyltransferase activity: Identification and biological properties. J Med Chem 49:6897-6907.
48. Marks PA, Richon VM, Breslow R, Rifkind RA. 2001a. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13:477-483.
49. Marks PA, Rifkind RA, Richon VM, Breslow R. 2001b. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin Cancer Res 7:759-760.
50. Marmorstein R, Roth SY. 2001. Histone acetyltransferases: Function, structure, and catalysis. Curr Opin Genet Dev 11:155-161.
51. Murata T, Kurokawa R, Krones A, Tatsumi K, Ishii M, Taki T, Masuno M, Ohashi H, Yanagisawa M, Rosenfeld MG, Glass CK, Hayashi Y. 2001. Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. Hum Mol Genet 10:1071-1076.
52. Nakatani F, Tanaka K, Sakimura R, Matsumoto Y, Matsunobu T, Li X, Hanada M, Okada T, Iwamoto Y. 2003. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 278:15105-15115.
53. Nugent MA, Iozzo RV. 2000. Fibroblast growth factor-2. Int J Biochem Cell Biol 32:115-120.
54. Nugent MA, Forsten-Williams K, Karnovsky MJ, Edelman ER. 2005. Mechanisms of cell growth regulation by heparin and heparan sulfate. In: Garg HG, editor. Chemistry and biology of heparin and heparan sulfate. Oxford, UK: Elsevier Ltd. pp 533-570.
55. Pal PK, Starr T, Gertler MM. 1983. Neutralization of heparin by histone and its subfractions. Thromb Res 31:69-79.
56. Park PW, Reizes O, Bernfield M. 2000. Cell surface heparan sulfate proteoglycans: Selective regulators of ligand-receptor encounters. J Biol Chem 275:29923-29926.
57. Rapraeger A, Bernfield M. 1985. Cell surface proteoglycan of mammary epithelial cells. Protease releases a heparan sulfate-rich ectodomain from a putative membrane-anchored domain. J Biol Chem 260:4103-4109.
58. Rapraeger A, Yeaman C. 1989. A quantitative solid-phase assay for identifying radiolabeled glycosaminoglycans in crude cell extracts. Anal Biochem 179:361-365.
59. Richardson TP, Trinkaus-Randall V, Nugent MA. 2001. Regulation of heparan sulfate proteoglycan nuclear localization by fibronectin. J Cell Sci 114:1613-1623.
60. Roth SY, Denu JM, Allis CD. 2001. Histone acetyltransferases. Annu Rev Biochem 70:81-120.
61. Speranza A, Pellizzaro C, Coradini D. 2005. Hyaluronic acid butyric esters in cancer therapy. Anticancer Drugs 16:373-379.
62. Sperinde GV, Nugent MA. 1998. Heparan sulfate proteoglycans control bFGF processing in vascular smooth muscle cells. Biochemistry 37: 13153-13164.
63. Sperinde GV, Nugent MA. 2000. Mechanisms of FGF-2 intracellular processing: A kinetic analysis of the role of heparan sulfate proteoglycans. Biochemistry 39:3788-3796.
64. Stimson L, Rowlands MG, Newbatt YM, Smith NF, Raynaud FI, Rogers P, Bavetsias V, Gorsuch S, Jarman M, Bannister A, Kouzarides T, McDonald E, Workman P, Aherne GW. 2005. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther 4:1521-1532.
65. Sun JM, Spencer VA, Chen HY, Li L, Davie JR. 2003. Measurement of histone acetyltransferase and histone deacetylase activities and kinetics of histone acetylation. Methods 31:12-23.
66. Thompson PR, Kurooka H, Nakatani Y, Cole PA. 2001. Transcriptional coactivator protein p300. Kinetic characterization of its histone acetyltransferase activity. J Biol Chem 276:33721-33729.
67. Turnbull J, Powell A, Guimond S. 2001. Heparan sulfate: Decoding a dynamic multifunctional cell regulator. Trends Cell Biol 11:75-82.
68. Villeponteau B. 1992. Heparin increases chromatin accessibility by binding the trypsin-sensitive basic residues in histones. Biochem J 288(Pt 3):953-958.
69. Watson K, Gooderham NJ, Davies DS, Edwards RJ. 1999. Nucleosomes bind to cell surface proteoglycans. J Biol Chem 274:21707-21713.
70. Wong LJ, Wong SS. 1983. Kinetic mechanism of the reaction catalyzed by nuclear histone acetyltransferase from calf thymus. Biochemistry 22:4637-4641.
71. Yang XJ. 2004. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res 32:959-976.
72. Yukioka M, Sasaki S, Qi SL, Inoue A. 1984. Two species of histone acetyltransferase in rat liver nuclei. J Biol Chem 259:8372-8377.